snehalathad
/
KonectarEvents
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity
KonectarEvents/assets/topicnotes.json

515 lines
30 KiB
JSON
Raw Permalink Normal View History

first commit
2024-09-06 06:30:31 +00:00
{
"data": {
"notes":
[
{
"kol_event_id": "378748",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Debate: Car T Should Be Reserved For Late Relapse > 3 Lines",
"note": "The speaker suggested that CAR T-cell therapy should be reserved for patients who had a late relapse, rather than being used early in their treatment.",
"event_id": "23423",
"speakerr_name": "Saad Z Usmani",
"hcpid": ""
},
{
"kol_event_id": "378609",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Secondary Aml - Best Therapy",
"note": "The speaker discussed secondary AML and the most effective treatment approaches for managing it.",
"event_id": "23423",
"speakerr_name": "Pinkal Desai",
"hcpid": ""
},
{
"kol_event_id": "378613",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "All Use Of Ngs In Mrd",
"note": "The speaker discussed how Next-Generation Sequencing (NGS) is used to detect and monitor Minimal Residual Disease (MRD) across various cancers.",
"event_id": "23423",
"speakerr_name": "Aaron C Logan",
"hcpid": ""
},
{
"kol_event_id": "378674",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Measuring Residual Disease – Mrd, Mass Fix, Etc",
"note": "The speaker discussed the use of Mass Cytometry (Mass Fix) for detecting and treating Minimal Residual Disease (MRD).",
"event_id": "23423",
"speakerr_name": "Ajay K Nooka",
"hcpid": ""
},
{
"kol_event_id": "378746",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Frontline Therapy - Quads For Everyone? Te/Ti",
"note": "The speaker discussed evaluating the effectiveness and determining the intensity of frontline therapy, including quadruplet therapy (a combination of four drugs), for cancer treatment.",
"event_id": "23423",
"speakerr_name": "Ajay K Nooka",
"hcpid": ""
},
{
"kol_event_id": "378813",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Haploidentical Transplant Should Be The Cell Therapy Choice For Sickle Cell Disease",
"note": "The speaker discussed why haploidentical transplant should be considered the preferred cell therapy option for sickle cell disease.",
"event_id": "23423",
"speakerr_name": "Adetola Kassim",
"hcpid": ""
},
{
"kol_event_id": "378811",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Cellular Therapy",
"note": "The speaker discussed cellular therapy and its various types that are effective in treating cancer.",
"event_id": "23423",
"speakerr_name": "Adetola Kassim",
"hcpid": ""
},
{
"kol_event_id": "378712",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Azacytidine Plus Venetoclax Should Be Prescribed As Listed On The Label",
"note": "The speaker discussed that azacytidine and venetoclax should be used together according to the specific guidelines and dosages outlined in their official labeling.",
"event_id": "23423",
"speakerr_name": "Keith Pratz",
"hcpid": ""
},
{
"kol_event_id": "378758",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Debate: Can Therapy With Btki Be Discontinued: No",
"note": "The speaker discussed the potential discontinuation of BTK inhibitor therapy, emphasizing its critical role in managing certain cancers and the associated risks.",
"event_id": "23423",
"speakerr_name": "Kerry A Rogers",
"hcpid": ""
},
{
"kol_event_id": "378621",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Car T-Cell Therapy After Car T-Cell Therapy For Dlbcl",
"note": "The speaker discussed administering a second round of CAR T-cell therapy for patients with diffuse large B-cell lymphoma (DLBCL) who relapse or do not respond to their initial CAR T-cell treatment.",
"event_id": "23423",
"speakerr_name": "Frederick Locke",
"hcpid": ""
},
{
"kol_event_id": "378741",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Long-Term Clinical Data From Multiple Phase 3 Trails For Calquence In The Treatment Of Cll/Sll",
"note": "The speaker discussed clinical data from multiple Phase 3 trials of Calquence in the treatment of CLL/SLL, focusing on its efficacy and safety.",
"event_id": "23423",
"speakerr_name": "Moshe Yair Levy",
"hcpid": ""
},
{
"kol_event_id": "378805",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Car T Cell Therapy For Second-Line (2L) Lbcl",
"note": "The speaker discussed using CAR T-cell therapy for patients with large B-cell lymphoma (LBCL) who have not responded to or have relapsed after first-line treatment.",
"event_id": "23423",
"speakerr_name": "Moshe Yair Levy",
"hcpid": ""
},
{
"kol_event_id": "378710",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Flt3 Mutated Aml Unanswered Questions",
"note": "The speaker provided insights into the ongoing uncertainties and unresolved issues in managing and treating acute myeloid leukemia (AML) with FLT3 mutations.",
"event_id": "23423",
"speakerr_name": "Mark J Levis",
"hcpid": ""
},
{
"kol_event_id": "375276",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "DDR inhibitor combinations",
"note": "The speaker discussed how DDR inhibitor combinations use drugs to block DNA Damage Response (DDR) pathways alongside other treatments to enhance cancer therapy.",
"event_id": "23419",
"speakerr_name": "Timothy Anthony Yap",
"hcpid": ""
},
{
"kol_event_id": "375033",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Phase 1b/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors",
"note": "The speaker discussed the safety and efficacy of combining the CDK4-selective inhibitor PF-07220060 and the CDK2-selective inhibitor PF-07104091 for treating HR+ HER2- metastatic breast cancer and advanced solid tumors.",
"event_id": "23419",
"speakerr_name": "Timothy Anthony Yap",
"hcpid": ""
},
{
"kol_event_id": "374874",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Phase 1b study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)",
"note": "The speaker discussed the use of NT-I7, a long-acting IL-7, following CD19-directed CAR T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL).",
"event_id": "23419",
"speakerr_name": "Armin Ghobadi",
"hcpid": ""
},
{
"kol_event_id": "375154",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors",
"note": "The speaker provided insights into the ALKOVE-1 Study, which examined NVL-655 as a treatment for ALK-positive (ALK+) solid tumors, focusing on its safety and efficacy.",
"event_id": "23419",
"speakerr_name": "Alexander E. Drilon",
"hcpid": ""
},
{
"kol_event_id": "375492",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Is there a role for radiation therapy in advanced RCC?",
"note": "The speaker discussed the potential benefits and applications of radiation therapy in treating advanced renal cell carcinoma (RCC).",
"event_id": "23419",
"speakerr_name": "Chad Tang",
"hcpid": ""
},
{
"kol_event_id": "374951",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Novel data in the field of immune checkpoint blockade for eTNBC",
"note": "The speaker discussed new research on immune checkpoint blockade for early-stage triple-negative breast cancer (eTNBC), examining its effectiveness and safety.",
"event_id": "23419",
"speakerr_name": "Sara M. Tolaney",
"hcpid": ""
},
{
"kol_event_id": "374984",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Racial Disparities in immune-related adverse events in patients with lung cancer treated with Immune checkpoint inhibitors.",
"note": "The speaker discussed variations in the frequency, severity, and outcomes of side effects among patients of different racial backgrounds who were treated with immune checkpoint inhibitors for lung cancer.",
"event_id": "23419",
"speakerr_name": "Hina Khan",
"hcpid": ""
},
{
"kol_event_id": "374898",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study",
"note": "The speaker discussed results from an expanded Phase 1 study on botensilimab plus balstilimab in patients with refractory metastatic sarcoma, focusing on the efficacy and safety of these treatments.",
"event_id": "23419",
"speakerr_name": "Breelyn A. Wilky",
"hcpid": ""
},
{
"kol_event_id": "375063",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition",
"note": "The speaker discussed ongoing research into new treatments for advanced breast cancer patients who had progressed after endocrine therapy and CDK4/6 inhibitors.",
"event_id": "23419",
"speakerr_name": "Joyce O'Shaughnessy",
"hcpid": ""
},
{
"kol_event_id": "375270",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Phase I, Two-Part, Multicenter First-In-Human (FIH) Study of TORL-1-23, A Novel Claudin 6 (CLDN6) Targeting Antibody Drug Conjugate (ADC) In Patient With Advanced Solid Tumors.",
"note": "The speaker provided insights into the study of TORL-1-23, a novel Claudin 6 (CLDN6) targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.",
"event_id": "23419",
"speakerr_name": "Gottfried E. Konecny",
"hcpid": ""
},
{
"kol_event_id": "375519",
"eid": "",
"name": "2024 European Society for Medical Oncology Congress (ESMO)",
"session_name": "Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)",
"note": "The speaker provided insights into BMS-986365 (CC-94676), a drug that targets and degrades the androgen receptor, and its evaluation in patients with metastatic castration-resistant prostate cancer (mCRPC) who had already received multiple treatments.",
"event_id": "23419",
"speakerr_name": "Dana Rathkopf",
"hcpid": ""
},
{
"kol_event_id": "359866",
"eid": "",
"name": "2024 American Society of Colon and Rectal Surgeons Annual Scientific Meeting (ASCRS)",
"session_name": "Results Of ctDNA As A Predictive Biomarker In Adjuvant Chemotherapy In Stage II Colon Cancer: NRG-GI005 (COBRA) Phase II/III study",
"note": "The speaker provided insights into the NRG-GI005 (COBRA) study, which investigates how circulating tumor DNA (ctDNA) can predict patient outcomes and inform the use of adjuvant chemotherapy for Stage II colon cancer.",
"event_id": "23381",
"speakerr_name": "Dustin A. Deming",
"hcpid": ""
},
{
"kol_event_id": "359327",
"eid": "",
"name": "2024 American Society of Colon and Rectal Surgeons Annual Scientific Meeting (ASCRS)",
"session_name": "A Comparative Analysis of Laparoscopic and Ultrasound-Guided TAP Blocks in Minimally Invasive Colorectal Surgery in a Community Hospital",
"note": "The speaker compared the effectiveness and outcomes of laparoscopic versus ultrasound-guided TAP blocks for minimally invasive colorectal surgery at a community hospital.",
"event_id": "23381",
"speakerr_name": "Robert J. Yu",
"hcpid": ""
},
{
"kol_event_id": "369679",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Impact of left ventricular lead position on echocardiographic response after upgrading from right to biventricular pacing - Insights from the BUDAPEST CRT Upgrade Trial",
"note": "The speaker highlighted that optimal left ventricular (LV) lead placement during upgrades from right ventricular (RV) pacing to biventricular pacing significantly improves the effectiveness of cardiac resynchronization therapy (CRT), leading to better patient outcomes such as improved heart function and exercise capacity.",
"event_id": "23418",
"speakerr_name": "Bela Merkely",
"hcpid": ""
},
{
"kol_event_id": "374402",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study",
"note": "The speaker provided insights into how the INTERASPIRE study revealed important information about lipoprotein(a) [Lp(a)] levels and their impact on coronary heart disease (CHD) across different populations.",
"event_id": "23418",
"speakerr_name": "Kausik K. Ray",
"hcpid": ""
},
{
"kol_event_id": "369775",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "The prognosis evaluation of guideline-directed medical therapy for type 2 acute myocardial infarction patients with acute respiratory failure",
"note": "The speaker provided insights into how following guideline-directed medical therapy (GDMT) impacted the prognosis of patients with type 2 acute myocardial infarction (MI) and acute respiratory failure.",
"event_id": "23418",
"speakerr_name": "Kang-Yin Chen",
"hcpid": ""
},
{
"kol_event_id": "373670",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Ultrasound-guided versus palpation-guided techniques for vessel catheterization in children undergoing cardiac surgery. A systematic review and meta-analysis of randomized controlled trials.",
"note": "The speaker compared ultrasound-guided and palpation-guided techniques for vessel catheterization in children undergoing cardiac surgery by evaluating randomized controlled trials to identify which method is more effective.",
"event_id": "23418",
"speakerr_name": "Mohamed Abouzid",
"hcpid": ""
},
{
"kol_event_id": "374647",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Predictors and Outcomes of Atrial Fibrillation Progression in Patients with Device-Detected Subclinical AF: Insights from the ARTESiA Trial",
"note": "The speaker shared insights from the ARTESiA trial, which forecasts the outcomes related to the progression of atrial fibrillation (AF) in patients with device-detected subclinical AF.",
"event_id": "23418",
"speakerr_name": "Giuseppe Boriani",
"hcpid": ""
},
{
"kol_event_id": "378748",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Debate: Car T Should Be Reserved For Late Relapse > 3 Lines",
"note": "The speaker argued that reserving CAR T-cell therapy for late relapse cases optimized its impact and ensured that it was used in the most appropriate clinical scenarios.",
"event_id": "23423",
"speakerr_name": "Saad Z Usmani",
"hcpid": ""
},
{
"kol_event_id": "378613",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "All Use Of Ngs In Mrd",
"note": "The speaker talked about how using NGS for MRD detection provided a high-resolution view of genetic mutations and abnormalities, which helped in assessing treatment response and guiding further therapeutic decisions.",
"event_id": "23423",
"speakerr_name": "Aaron C Logan",
"hcpid": ""
},
{
"kol_event_id": "378712",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Azacytidine Plus Venetoclax Should Be Prescribed As Listed On The Label",
"note": "The speaker talked about the necessity of adhering to the dosing and administration guidelines outlined on the label to ensure the treatment's efficacy and safety.",
"event_id": "23423",
"speakerr_name": "Keith Pratz",
"hcpid": ""
},
{
"kol_event_id": "378621",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Car T-Cell Therapy After Car T-Cell Therapy For Dlbcl",
"note": "The speaker was likely focusing on the considerations, challenges, and potential strategies for using CAR T-cell therapy again in patients with DLBCL who had previously undergone this treatment.",
"event_id": "23423",
"speakerr_name": "Frederick Locke",
"hcpid": ""
},
{
"kol_event_id": "378674",
"eid": "",
"name": "2024 Society of Hematologic Oncology Annual Meeting (SOHO)",
"session_name": "Measuring Residual Disease – Mrd, Mass Fix, Etc",
"note": "The speaker discussed the Mass Fix technique and how it contributed to monitoring and managing residual disease in cancer patients, enhancing treatment outcomes, and personalizing therapy.",
"event_id": "23423",
"speakerr_name": "Ajay K Nooka",
"hcpid": ""
},
{
"kol_event_id": "369679",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Impact of left ventricular lead position on echocardiographic response after upgrading from right to biventricular pacing - Insights from the BUDAPEST CRT Upgrade Trial",
"note": "The speaker conveyed how the position of the LV lead impacted the effectiveness of biventricular pacing as measured by echocardiographic improvements, based on findings from the BUDAPEST CRT Upgrade Trial.",
"event_id": "23418",
"speakerr_name": "Bela Merkely",
"hcpid": ""
},
{
"kol_event_id": "374402",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study",
"note": "The speaker gave a comprehensive view of Lp(a) levels in relation to coronary heart disease, utilizing data from the INTERASPIRE Study to highlight global trends, implications for cardiovascular risk management, and the need for further research to address these issues.",
"event_id": "23418",
"speakerr_name": "Kausik K. Ray",
"hcpid": ""
},
{
"kol_event_id": "369775",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "The prognosis evaluation of guideline-directed medical therapy for type 2 acute myocardial infarction patients with acute respiratory failure",
"note": "The speaker discussed how guideline-directed medical therapy (GDMT) affects the prognosis of patients with type 2 acute myocardial infarction (AMI) who also suffer from acute respiratory failure.",
"event_id": "23418",
"speakerr_name": "Kang-Yin Chen",
"hcpid": ""
},
{
"kol_event_id": "373670",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Ultrasound-guided versus palpation-guided techniques for vessel catheterization in children undergoing cardiac surgery. A systematic review and meta-analysis of randomized controlled trials.",
"note": "The speaker conveyed the findings of a systematic review and meta-analysis comparing ultrasound-guided versus palpation-guided techniques for vessel catheterization in children undergoing cardiac surgery, focusing on which method proved more effective, safer, and preferable in clinical practice based on the evidence.",
"event_id": "23418",
"speakerr_name": "Mohamed Abouzid",
"hcpid": ""
},
{
"kol_event_id": "374647",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Predictors and Outcomes of Atrial Fibrillation Progression in Patients with Device-Detected Subclinical AF: Insights from the ARTESiA Trial",
"note": "The speaker discussed the predictors and outcomes of atrial fibrillation (AF) progression in patients with device-detected subclinical AF, drawing insights from the ARTESiA Trial. ",
"event_id": "23418",
"speakerr_name": "Giuseppe Boriani",
"hcpid": ""
},
{
"kol_event_id": "371184",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Performance of an automated echocardiographic artificial intelligence model. to detect subclinical heart failure with preserved ejection fraction (HFpEF) in community-dwelling older adults",
"note": "The speaker discussed how effectively an automated echocardiographic artificial intelligence (AI) model detects subclinical heart failure with preserved ejection fraction (HFpEF) in older adults.",
"event_id": "23418",
"speakerr_name": "Ambarish Pandey",
"hcpid": ""
},
{
"kol_event_id": "370813",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Red cell distribution width as a predictor of cardiovascular events in high-risk patients with statin intolerance: post-hoc analysis of the CLEAR Outcomes trial",
"note": "The speaker discussed the potential of red cell distribution width (RDW) as a predictor of cardiovascular events in high-risk patients with statin intolerance, drawing on a post-hoc analysis of the CLEAR Outcomes trial.",
"event_id": "23418",
"speakerr_name": "Patrick Moriarty",
"hcpid": ""
},
{
"kol_event_id": "374565",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure",
"note": "The speaker discussed the RESHAPE-HF2 trial, which focused on using percutaneous repair techniques to treat moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure.",
"event_id": "23418",
"speakerr_name": "Stefan Anker",
"hcpid": ""
},
{
"kol_event_id": "374169",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "Transcatheter edge-to-edge repair (TEER) is failing in the mitral: re-intervention or surgical rescue",
"note": "The speaker discussed the challenges of transcatheter edge-to-edge repair (TEER) failure for mitral valve repair and explored options for addressing this, including re-intervention or surgical rescue.",
"event_id": "23418",
"speakerr_name": "Ran Kornowski",
"hcpid": ""
},
{
"kol_event_id": "372860",
"eid": "",
"name": "2024 European Society of Cardiology Congress (ESC)",
"session_name": "STOP-or-NOT - Impact of renin-angiotensin system inhibitors continuation versus discontinuation on postoperative complications: a multicenter randomised, controlled trial",
"note": "The speaker discussed the STOP-or-NOT trial, which investigated the impact of continuing versus discontinuing renin-angiotensin system (RAS) inhibitors on postoperative complications.",
"event_id": "23418",
"speakerr_name": "Matthieu Legrand",
"hcpid": ""
}
]
}
}